Compare Charles River Laboratories Intl. Inc (CRL) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Wahed FTSE USA Shariah ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Wahed FTSE USA Shariah ETF trades at $75.9 (market cap $1.00B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 14.2× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is more actively traded (51,137 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Wahed FTSE USA Shariah ETF for 66 Days on average.
| CRL | HLAL | |
|---|---|---|
Market Cap | $14.23B | $1.00B |
Volume | 1,176,885 | 51,137 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $76.54 |
52-Week Low | $149.93 | $57.46 |
Typical Hold Time | 33 Days | 66 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
